With 4 more biotech IPOs due to wrap up Q2, how is the class of 2019 faring?
With 22 biotech IPOs on the books and four more set to price in the last week of June, investment adviser Renaissance Capital has taken …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
